European MedTech Intelligence
Decoding Capital Flows, AI Governance, and Commercialization.
Market intelligence bridging the gap between clinical validation and scalable market access.
-
Europe MedTech News: Xsensio funding, FARAPULSE CE mark, and UK NICE policy (Week of Mar 2-8, 2026, #27)
A week in which Swiss sensors found deep pockets, “boring” logistics became interesting, and Europe’s commercialization machine kept reminding everyone that market access is only the beginning. Weekly snapshot of…
-
Europe MedTech & Digital Health Weekly Brief (Week of Feb 23–Mar 1, 2026, #26)
This week: Europe writes bigger cheques for edge AI, surgeons get sharper intra-op vision, and regulators quietly upgrade the “plumbing” that makes scale possible. People on the move Precision IO…
-
Europe MedTech & Digital Health Weekly Brief (Week of Feb 16-22, 2026, #25)
Compliance tooling and workflow automation quietly had a massive week, capped off by the UK’s loud return to the CE mark conversation with a push for indefinite regulatory recognition. People…
-
Europe MedTech & Digital Health Weekly Brief (Week of Feb 9–15, 2026, #24)
European healthcare shifts from “growth at all costs” toward commercial execution as precision pathology, ocular structural integrity, and public-market readiness dominate the landscape. People on the move Amadeus Capital Partners…
-
Europe MedTech & Digital Health Weekly Brief (Week of Feb 2–8, 2026, #23)
Clinical-trial AI cash, senior care safety tech, and a trio of MDR certifications: Europe’s week mixed capital, commercialization, and infrastructure-level digital transformation. People on the move Guerbet Karim Boussebaa appointed…
-
Breaking the “Rule 11” Bottleneck: The New Era for AI in Medical Imaging
For years, European imaging AI founders have been trapped by Rule 11 of the MDR, which effectively pushed almost all diagnostic software into Class IIa or higher. However, the regulatory…
The Sunday European MedTech Brief
Join commercial leaders and investors receiving actionable intelligence on capital flows, AI governance, and MDR/IVDR bottlenecks.
No spam. Just high-signal market intelligence. Unsubscribe anytime.